Use of anti-CD20 therapy in follicular and marginal zone lymphoma: a review of the literature
| Autor: | Keina S. Quiroz‐Cervantes, Luis Miguel Juárez-Salcedo, Diego Conde-Royo, Samir Dalia |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Oncology
medicine.medical_specialty medicine.medical_treatment Review anti-cd20 03 medical and health sciences 0302 clinical medicine Antigen immune system diseases Internal medicine hemic and lymphatic diseases medicine Indolent Non-Hodgkin Lymphoma biosimilars Progenitor cell Adverse effect Pharmacology CD20 biology business.industry lcsh:RM1-950 Biosimilar General Medicine Immunotherapy lcsh:Therapeutics. Pharmacology 030220 oncology & carcinogenesis biology.protein Molecular Medicine Rituximab immunotherapy business indolent non-hodgkin lymphoma 030215 immunology medicine.drug |
| Zdroj: | Drugs in Context, Vol 9, Pp 1-12 (2020) Drugs in Context |
| ISSN: | 1740-4398 |
| Popis: | The identification of the CD20 antigen in 1979 was the first step in what would become a therapeutic milestone opening the use of immunotherapy in hematological diseases. This protein is expressed on the surface of developing B cells, but not the early progenitors or mature plasma cells. In 1997, rituximab was approved by the Food and Drug Administration, and since then it has revolutionized the treatment of B-cell malignancies. It is used as a monotherapy and in combination, at induction, at relapsed, and also in maintenance. Indolent non-Hodgkin lymphomas are characterized by a long and non-aggressive course. In this group of lymphomas, rituximab represented a great therapeutic improvement, achieving lasting responses with few adverse effects. Nowadays, second-generation molecules are emerging that may have important advantages compared to rituximab, as well as biosimilars that represent an important cost-effective option. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|